Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)

Personalis, Inc. (NASDAQ:PSNL) is among the 12 Best Genomics Stocks to Invest In.

The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titchmarsh took over coverage of Personalis, Inc. (NASDAQ:PSNL) with an Equal Weight rating and a price objective of $11, up from $9. The firm identified several upcoming catalysts within its coverage universe starting in 2026 and outlined growing bright spots across life science instruments and diagnostics end markets. Morgan Stanley claimed that a valuation surge in the second half of the year left industry multiples at fair levels despite favorable sector dynamics, prompting the bank to start coverage with an In-Line industry stance.

In addition, Personalis, Inc. (NASDAQ:PSNL) lowered its full-year 2025 sales forecast from $70 million to $80 million to a range of $68 million to $73 million. The projected income from pharmaceutical testing, services, and other clients has been reduced from $52 million to $58 million to $50 million to $54 million.

In contrast to previous projections of $15 million to $16 million, revenue from population sequencing and enterprise clients was raised to $16.5 million to $17 million. Clinical test reimbursed revenue has dropped from $3 million to $6 million to $1.5 million to $2 million. Gross margin estimate of 22% to 24%, net loss of about $85 million, and cash consumption of about $75 million were all reiterated by the business.

Personalis, Inc. (NASDAQ:PSNL) offers genomic sequencing and analytics technologies to help develop tailored cancer vaccines and other next-generation cancer immunotherapies.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None